|
Evaluation of Patients with Unresolved Chromosome Abnormalities Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Evaluation of Patients with Unresolved Chromosome Abnormalities conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Evaluation of Patients with Unresolved Chromosome Abnormalities Clinical research trials and Evaluation of Patients with Unresolved Chromosome Abnormalities medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Evaluation of Patients with Unresolved Chromosome Abnormalities. Evaluation of Patients with Unresolved Chromosome Abnormalities Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Evaluation of Patients with Unresolved Chromosome Abnormalities clinical trial. Subjects often receive the most expert healthcare possible for their Evaluation of Patients with Unresolved Chromosome Abnormalities condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Evaluation of Patients with Unresolved Chromosome Abnormalities  Evaluation of Patients with Unresolved Chromosome Abnormalities
Evaluation of Patients with Unresolved Chromosome Abnormalities
For Condition: Abnormalities,Failure to Thrive,Mental Retardation,Microcephaly
Status: Completed
Sponsor(s): National Human Genome Research Institute (NHGRI) ,
Synopsis: The purpose of this research is to study a new way to test for chromosome abnormalities. Chromosomes are strands of DNA (the genetic material in the cell nucleus) that are made up of genes-the units of heredity. Chromosome abnormalities are usually investigated by staining the chromosomes with a dye (Giemsa stain) and examining them under a microscope. This method can detect many duplications and deletions of pieces of chromosomes and is very accurate in diagnosing certain abnormalities. It is not useful, however, for identifying very small abnormalities. This study will evaluate the accuracy of a test method using 24 different dyes for finding small chromosome abnormalities. Children and adults with various chromosome abnormalities may be eligible for this study, including, for example, people with developmental delay or mental retardation, abnormal growth features or growth retardation, and certain behavioral disorders. Participants will be evaluated in the clinic over a 1- to 3-day period, depending on their symptoms. All participants will be examined by a genetics specialist and will have a physical examination and possibly X-rays, computerized tomography (CT) scans, magnetic resonance imaging (MRI), ultrasound studies and medical photography. Blood will be drawn for chromosome testing-about 3 tablespoons from adults and 1 to 3 teaspoons from children. When the test results are available, participants will return to the clinic for follow-up evaluation and review of the test findings. The genetic and medical evaluations, along with their implications, will be discussed.
Details: There is a range of genomic aberrations from aneuploidy down to single base pair deletions or inserts. Present technology uses microscopic cytogenetics for detection of large rearrangements (greater than 2 Mb) and molecular techniques for small rearrangements (less than 2 Mb). There is a gap in practical diagnostic technology in that microscopic cytogenetics has poor sensitivity for aberrations less than 5 Mb and the molecular techniques are cumbersome for clinical use in the megabase range. In many cases it is possible to determine that an aberration is present by microscopic cytogenetics but cannot be characterized. We propose to use Spectral Karyotyping (SKY) and supplementary FISH and molecular techniques to characterize these aberrations. Subjects will be seen in OP9 for a clinical genetics evaluation and phlebotomy for SKY. Confirmation of SKY results will be performed by standard FISH, genomic content mapping, and other standard techniques.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Physical anomalies or developmental anomalies. Karyotype showing derivative chromosome abnormality that is not fully characterized. No abnormal parental karyotype. No prenatal specimens. Probands of all ages, genders, and ethnic origin are eligible. The proband must have a non-mosaic abnormal G-banded chromosome analysis of good quality that shows one or more derivative chromosomes whose foreign component cannot be determined by standard G-banding techniques. The parents should also have G-banded chromosome analysis prior to eligibility for consent 2. If this has not been done by the referring physician, it may be done as part of the protocol. The proband with the abnormal karyotype should have one or more of the following features: dysmorphic features; developmental delay or mental retardation; growth retardation, microephaly, short stature or failure to thrive; behavioral disorder Biological parents must be willing to supply a blood specimen. If they have any of the features listed above, they must attend the clinic if the proband is to be eligible. The proband must be evaluated by the NCHGR clinical genetics service by the PI, a co-investigator, or his associates. Mothers will be queried about potential non-paternity. If non-paternity is possible, the family will need to undergo clinical paternity evaluation before they are enrolled in the study.
Total Enrollment: 263
Location and Contact Information:
National Human Genome Research Institute (NHGRI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 970045; 97-HG-0045
Study Start Date: December 23, 1996
Record last reviewed: October 16, 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001639
Other Abnormalities Studies:
1. Evaluation of Patients with Unresolved Chromosome Abnormalities
Related Studies:
Other Abnormalities Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Evaluation of Patients with Unresolved Chromosome Abnormalities
|
|
|
|
|
|
|
|
